

# SOFIVA Cancer Monitor-Colon Cancer

Assessments for FDA-approved drug for Colon cancer ,  
Specimen type could be tissue and body fluid.

## ■ Gene list (26 genes)

|        |   |        |     |        |     |        |   |       |   |
|--------|---|--------|-----|--------|-----|--------|---|-------|---|
| AKT1   | ● | AKT2   | ●   | APC    | ●   | BRAF   | ● | CCND1 | ● |
| CTNNB1 | ● | DPYD   | ●   | ERBB2  | ● ● | FBXW7  | ● | GNAS  | ● |
| KRAS   | ● | MAP2K1 | ●   | MLH1   | ●   | MSH2   | ● | MSH6  | ● |
| NRAS   | ● | NTRK1  | ● ● | PIK3CA | ●   | PIK3R1 | ● | PMS2  | ● |
| PTEN   | ● | RET    | ● ● | RNF43  | ●   | SMAD4  | ● | TP53  | ● |
| UGT1A1 | ● |        |     |        |     |        |   |       |   |

● SNV and InDel analysis; Fusion analysis ● / CNV analysis ●

## ■ Specification

| Specimen            | Blood,Body fluid(ctDNA)                       | FFPE    |
|---------------------|-----------------------------------------------|---------|
| Technology          | Hybrid capture-based NGS + Sanger Sequencing* |         |
| Average reads       | >6,000x                                       | >3,600x |
| Analytical variants | SNV / InDel / CNV / Fusion                    |         |
| Sensitivity         | 99.0%                                         |         |
| Turnaround time     | 10 working days**                             |         |

\* To clarify whether a mutation is a germline mutation or a somatic mutation.

\*\*10 working days after qualified specimens are collected.

## ■ Features

| NGS Testing of Colon Cancer | SOFIVA Cancer Monitor -Colon Cancer                                                                                                                   | Advantages                                                                                                              |
|-----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------|
| Specimen                    | <ul style="list-style-type: none"> <li>● FFPE</li> <li>★ Blood (ctDNA)</li> <li>★ Body fluid (pleural fluid, pleural effusion, etc.,ctDNA)</li> </ul> | ctDNA is suitable for SNV / InDel / CNV / Fusion analysis.                                                              |
| Technology                  | ★ Hybrid capture-based NGS                                                                                                                            | High overlapping probe is used to comprehensively detect possible gene variations.                                      |
| Tested genes                | 26 genes                                                                                                                                              | This item could help doctors determine the treatment strategy of FDA-approved drug for colon cancer for their patients. |
| Analytical variants         | SNV / InDel / CNV / Fusion                                                                                                                            | Multiple specimen types, tissue or ctDNA could be analyzed.                                                             |
| Turnaround time             | 10 working days                                                                                                                                       | Report is got quickly.                                                                                                  |
| Patient condition:          | <ul style="list-style-type: none"> <li>Insufficient tissue specimens</li> <li>Unable to re-sampling</li> </ul>                                        |                                                                                                                         |
|                             | ctDNA analysis using liquid biopsy is available, and the specimens could be blood, pleural fluid, pleural effusion, etc.                              | NGS testing is available even if there is not enough tumor tissue in last stage patient.                                |

# SOFIVA Cancer Monitor-Colon Cancer

## Features and Procedure

### ■ Information for targeted therapy : NGS panel tests can evaluate multiple genes simultaneously



Specimen type could be tissue and blood.



Multi-gene detection is time-saving and instant.



Both germline and somatic mutation can be detected.

### ■ SOFIVA Cancer Monitor-Colon Cancer : assessments for FDA-approved drug

#### Colon Cancer

Targeted therapies listed in NCCN guideline<sup>1</sup>

|          |                         |
|----------|-------------------------|
| BRAF     | Encorafenib + Cetuximab |
| ERBB2    | Tucatinib + Trastuzumab |
| KRAS(WT) | Cetuximab               |
| NRAS(WT) | Panitumumab             |

#### Solid Tumors

|                     |                                                            |
|---------------------|------------------------------------------------------------|
| BRAF V600E Mutation | Dabrafenib+Trametinib(Not indicated for colorectal cancer) |
| NTRK Fusion         | Entrectinib, Larotrectinib                                 |
| RET Rearrangement   | Selpercatinib                                              |

### ■ Panel selection

Accurate and complete drug-related gene panel

#### SOFIVA Cancer Monitor -Breast Cancer

##### 26 genes

- Covers genes associated with targeted therapies for patients with colon cancer.
- Common mutations in colon cancer.
- MMR genes.

16 genes

Colon Cancer v1.0

#### SOFIVA Cancer Monitor v1.0

##### 31 genes

- Covers genes associated with common targeted therapies for patients with solid tumors.

**SOFIVA Cancer Monitor v2.1-** 77 genes: targeted therapies, potential clinical trial

**SOFIVA Cancer Monitor v3.0-** 249 genes: targeted therapies, potential clinical trial, monitoring

**SOFIVA CGP** – 324 genes + TMM + MSI : targeted therapies, immunotherapy, potential clinical trial

### ■ Procedure

Physician/ nurses explain procedures and contents

Sign the consent form and collect blood and FFPE specimen

Send specimen to SOFIVA GENOMICS

Analysis of experimental data

Report is produced in 10 working days

Reference:

1. NCCN Guidelines Colon Cancer Version 2. 2023



#### SOFIVA GENOMICS Medical Laboratory

T +886-2-2382-6615 ext.7 F +886-2-2382-6617  
No.27, Baoqing Rd., Zhongzheng Dist., Taipei City 100, Taiwan  
www.sofivagenomics.com

©2023.11 SOFIVA GENOMICS CO., LTD. All Right Reserved.

#### SOFIVA GENOMICS BANGKOK

T +66-2-258-5168 F +66-2-258-5368  
888 Polaris Tower, 4th Floor, Soi Sukhumvit 20, Sukhumvit Road, Khlong Toei, Bangkok 10110, Thailand  
www.sofivagenomics.com